Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cortex (Cor) [formerly CORX] -- Ignore unavailable to you. Want to Upgrade?

To: DavidCG who wrote (673)	11/7/1998 11:40:00 AM
From: Doug Markle	Respond to of 1255

Elan? They bought Athena Neurosciences. Are they trying to become a big neuro-pharm company? wild-ass speculation; anyone out there with "real" insight?

To: DavidCG who wrote (673)	11/8/1998 7:27:00 AM
From: Cage Rattler	Read Replies (1) \| Respond to of 1255

Dave: Thanks for the post. Where did you find out Soros is still on board? Indeed CORX may have hit bottom and could be on the way up. Sorry but just looking at the TA for CORX over the last two months (since May actually) one should note that they have never held a "support level" -- even during the recent Greenspan-inspired bull market. A short sale at any time during that period, even a few weeks back when you were staunchly defending them, and you would have made a wise trade and some big bucks. Right now I see support at about 30-cents -- perhaps, and hopefully, I am wrong. Even if CORX soars to 100-dollars, you can not excuse non-existant management to share-holder communication and the lack of real information they release. Re-read the paragraph you quoted from the quarterly release. Now ask yourself, what real information have they disclosed? None. "Continues to progress"? If past performance is an indicator, it will be later rather than soon as you suggest. Reads like an exam written by sophomore short on facts. It is the name of the game Dave, someone buys and someone sells based upon almost identical information. Ciao, Ted

To: DavidCG who wrote (673)	11/8/1998 12:44:00 PM
From: John Lacelle	Read Replies (1) \| Respond to of 1255

David, Actually, we know that. I think the paranoia you sense is that based upon the slide in the stock price, we think that the clinical trials for the drug "Ampalex" are not going well. I have invested in small biotech drug stocks over the years and my experience tells me that there is current insider information that is not good. Why else would we have seen a slide from ~$2.50 a share (a reasonable price for a risky stock) to <$0.50 per share (by any name, a penny-stock company in serious trouble). Of course, this is only guesswork but my instinct tells me that I am correct. -John BTW, There was an interesting article in this mornings "Parade" magazine about new drugs being used to treat Alzheimers disease.